Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study

BACKGROUND: Bisphosphonates have exhibited anti-tumor activity in non-small cell lung cancer (NSCLC). We aimed to evaluate whether the combination of bisphosphonates with tyrosine kinase inhibitors of EGFR (EGFR-TKIs) could obtain a synergistic effect on advanced NSCLC patients with EGFR mutations....

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chu-Ying, Wang, Li, Feng, Cheng-Jun, Yu, Ping, Cai, Xiao-Hong, Yao, Wen-Xiu, Xu, Yong, Liu, Xiao-Ke, Zhu, Wen-Jiang, Wang, Yan, Zhou, Jin, Lu, You, Wang, Yong-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341815/
https://www.ncbi.nlm.nih.gov/pubmed/26624882
http://dx.doi.org/10.18632/oncotarget.5515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341815/
https://www.ncbi.nlm.nih.gov/pubmed/26624882
http://dx.doi.org/10.18632/oncotarget.5515

Ejemplares similares